EP0617621A4 - Antagonistes de la cholecystokinine centrale possedant une efficacite pharmaceutique. - Google Patents

Antagonistes de la cholecystokinine centrale possedant une efficacite pharmaceutique.

Info

Publication number
EP0617621A4
EP0617621A4 EP92903432A EP92903432A EP0617621A4 EP 0617621 A4 EP0617621 A4 EP 0617621A4 EP 92903432 A EP92903432 A EP 92903432A EP 92903432 A EP92903432 A EP 92903432A EP 0617621 A4 EP0617621 A4 EP 0617621A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical effectiveness
cholecystokinin antagonists
central
central cholecystokinin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92903432A
Other languages
German (de)
English (en)
Other versions
EP0617621A1 (fr
Inventor
David Christopher Horwell
John Hughes
Geoff Neil Woodruff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Priority to EP96200242A priority Critical patent/EP0729752A2/fr
Publication of EP0617621A1 publication Critical patent/EP0617621A1/fr
Publication of EP0617621A4 publication Critical patent/EP0617621A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP92903432A 1991-12-20 1991-12-20 Antagonistes de la cholecystokinine centrale possedant une efficacite pharmaceutique. Withdrawn EP0617621A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96200242A EP0729752A2 (fr) 1991-12-20 1991-12-20 Antagonistes centraux de la cholecystokinine possédant une activité pharmaceutique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1991/009555 WO1993012791A1 (fr) 1991-12-20 1991-12-20 Antagonistes de la cholecystokinine centrale possedant une efficacite pharmaceutique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP96200242A Division EP0729752A2 (fr) 1991-12-20 1991-12-20 Antagonistes centraux de la cholecystokinine possédant une activité pharmaceutique

Publications (2)

Publication Number Publication Date
EP0617621A1 EP0617621A1 (fr) 1994-10-05
EP0617621A4 true EP0617621A4 (fr) 1995-04-05

Family

ID=22226062

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92903432A Withdrawn EP0617621A4 (fr) 1991-12-20 1991-12-20 Antagonistes de la cholecystokinine centrale possedant une efficacite pharmaceutique.

Country Status (3)

Country Link
EP (1) EP0617621A4 (fr)
JP (1) JPH07507993A (fr)
WO (1) WO1993012791A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207064T1 (de) * 1992-07-29 2001-11-15 Merck Sharp & Dohme Benzodiazepinderivate
FR2744361B1 (fr) * 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744363B1 (fr) * 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de thiazolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744362B1 (fr) * 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
TW442449B (en) 1996-07-04 2001-06-23 Hoechst Ag Process for preparing 1,2-dichloroethane by direct chlorination
WO2000073284A2 (fr) 1999-05-26 2000-12-07 Du Pont Pharmaceuticals Company Inhibiteurs de transcriptase inverse du vih a base de 1,4-benzodiazepin-2-ones
EP1749525A1 (fr) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Combination de pyrazoline substitués et de médicaments contre la dépendance
WO2007009691A2 (fr) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combinaison de substances active s
US8247438B2 (en) 2008-02-27 2012-08-21 Neuropill, Inc. Methods for treating schizophrenia
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (fr) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Inhibiteurs de bromodomaines et leurs utilisations
WO2012151512A2 (fr) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Inhibiteurs de bromodomaines et leurs utilisations
WO2012174487A2 (fr) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Inhibiteurs à bromodomaine et leurs utilisations
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
WO2013184878A1 (fr) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Inhibiteurs de bromo-domaine de benzo [b] isoxazoloazépines et applications associées
CN106687463B (zh) 2014-06-20 2019-04-09 星座制药公司 一种乙酰胺类化合物的晶型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411668A2 (fr) * 1989-08-04 1991-02-06 MERCK SHARP & DOHME LTD. Antagonistes centraux de cholécystokinin pour le traitement des troubles psychiatriques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663771A (en) * 1971-01-12 1972-05-16 Gulf & Western Industries Distributor rotor with improved contact securing means
NZ212436A (en) * 1984-06-25 1989-04-26 Rotta Research Lab D,l-glutamic and d,l-aspartic acid derivatives and pharmaceutical compositions
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
IT1215169B (it) * 1985-12-17 1990-01-31 Rotta Research Lab Derivati alchil ossigenati degli acidi glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione
CA2032427A1 (fr) * 1989-12-18 1991-06-19 Mark G. Bock Analogues de benzodiazepines
CA2032226A1 (fr) * 1989-12-18 1991-06-19 Mark G. Bock Analogues de la benzodiazepine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411668A2 (fr) * 1989-08-04 1991-02-06 MERCK SHARP & DOHME LTD. Antagonistes centraux de cholécystokinin pour le traitement des troubles psychiatriques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9312791A1 *

Also Published As

Publication number Publication date
JPH07507993A (ja) 1995-09-07
EP0617621A1 (fr) 1994-10-05
WO1993012791A1 (fr) 1993-07-08

Similar Documents

Publication Publication Date Title
FI922958A0 (fi) Farmaceutisk sammansaettning.
FI921060A0 (fi) Farmaceutiska aerosolformuleringar.
FI922252A0 (fi) Farmaceutisk sammansaettning.
FI922316A0 (fi) Farmaceutisk sammansaettning.
FI923581A0 (fi) Farmaceutisk kombinationsformation.
MX9102473A (es) Agentes farmaceuticos.
FI922364L (fi) Farmaceutiska kompositioner.
IT8921891A0 (it) Sistema di scarica.
FI901102A0 (fi) Farmaceutiska kompositioner.
MX9102421A (es) Sistema para montaje de recipiente distribuidor.
FI924405A0 (fi) Lhrh-antagonister.
IT8920486A0 (it) Composizioni farmaceutiche.
DZ1559A1 (fr) Compositions pharmaceutiques.
NO903241D0 (no) Sleideventil.
DE59202784D1 (de) Drehmeldesystem.
NO891130L (no) Doseringspumpesystem.
IT1230308B (it) Sistema stampante modulare.
FI943513A7 (fi) Kolekystokiniiniantagonisteina käyttökelpoisia 3-fenyyliureidoatsepin- 2-oneja ja -bentsatsepin-2-oneja
DE69012258D1 (de) Barriere des Kondensatortyps.
FI921785A0 (fi) Farmaceutisk foerening.
FI921786A0 (fi) Farmaceutisk foerening.
TR199601018A1 (tr) Farmasötik bilesikler.
FI905709A7 (fi) Torkparti i en maskin foer tillverkning av en kontinuerlig bana.
FR2683454B1 (fr) Composition pharmaceutique bactericide.
FI892345A7 (fi) Dispenseranordning.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950210

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19980630

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981111